Table 2. Meta-analysis comparing HCC with CTNNB1 mutation and wild-type.

Outcome of interest	No. of studies	Number of tissue samples	OR/WMD	95% CI	P value	I2(%)
Overall Survival [15–18, 20, 23]
1 year	6	CTNNB1 Mu=163, CTNNB1 Wt =866	0.52	0.34-0.81	0.004	18
3 year	6	CTNNB1 Mu=163, CTNNB1 Wt =866	0.28	0.18-0.42	<0.00001	0
5 year	6	CTNNB1 Mu=163, CTNNB1 Wt =866	-0.22	-0.37--0.06	0.005	81
Differentiation grade [15, 18, 19, 23–26, 28–30,]	10	CTNNB1 Mu=184, CTNNB1 Wt =680	0.54	0.36-0.81	0.003	0
TMN stage [15, 17, 18, 20, 22, 23, 25, 27, 28]	9	CTNNB1 Mu=174, CTNNB1 Wt =841	-0.25	-0.33--0.18	<0.00001	39
Metastasis [17, 22, 25, 26]	4	CTNNB1 Mu=69, CTNNB1 Wt =242	1.25	0.93-1.66	0.14	0
Vascular invasion [17, 22, 26]	3	CTNNB1 Mu=70, CTNNB1 Wt =223	1.42	0.82-2.45	0.21	43
Liver cirrhosis [19, 21, 22, 26]	4	CTNNB1 Mu=76, CTNNB1 Wt =138	0.21	0.11-0.39	<0.00001	0
Tumor size [19, 22, 25, 26, 28]	5	CTNNB1 Mu=67, CTNNB1 Wt =171	1.24	0.37-4.11	0.72	54
HBV [15, 17–19, 21, 23, 25–28, 30, 31]	12	CTNNB1 Mu=213, CTNNB1 Wt =795	0.44	0.31-0.64	<0.0001	0
HCV [15, 17, 21, 22, 25, 27, 28, 30, 31]	9	CTNNB1 Mu=111, CTNNB1 Wt =356	1.70	0.93-3.11	0.09	0

OR, odds ratio; WMD, weighted mean difference; CI, confidence interval; Mu, mutation; Wt, wild-type.